ArticleClinical practice and cases in emergency medicine2021
E-cigarettes and Vaping, Product-use Associated Lung Injury: A Case Series of Adolescents.
Article in Clinical practice and cases in emergency medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Global youth vaping and respiratory health: epidemiology, interventions, and policies.NPJ primary care respiratory medicine · 2022Review
- Vaping-Associated Lung Injury: A Review.Medicina (Kaunas, Lithuania) · 2022Review
- E-cigarette vaping associated acute lung injury (EVALI): state of science and future research needs.Critical reviews in toxicology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLung injury associated with the use of electronic cigarettes and vaping (EVALI) was first identified in 2019. Since then, clusters of cases have been reported in the literature. Our aim was to describe the clinical presentation of adolescents with EVALI in the emergency department and their clinical outcomes. CASE SERIES: In our case series, we identified seven adolescents diagnosed with EVALI. We describe their signs and symptoms on presentation to the emergency department and their clinical course. The most common symptoms on presentation were cough, shortness of breath, and vomiting. Each of these symptoms was seen in 71% of patients (n = 5), although not always together. Sinus tachycardia was noticed in 100% of patients (n = 7) and tachypnea in 85% (n = 6). While 85% (n = 6) required hospitalization for respiratory support, all patients were later discharged home on room air. After the diagnosis of EVALI, 85% of patients (n = 6) were treated with steroids.
conclusionEVALI is a new disease with unclear mechanisms that commonly presents with symptoms of cough, shortness of breath, and vomiting. It causes severe respiratory compromise in the adolescent population, requiring hospitalization and respiratory support.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.